Topical ocular delivery of TGF-β1 to the back of the eye: Implications in age-related neurodegenerative diseases

39Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Dysregulation of the transforming growth factor-β1 (TGF-β1)/selected small mother against decapentaplegic (SMAD) pathway can be implicated in development of age-related macular degeneration (AMD), and the delivery of TGF-β1 could be beneficial for AMD. We developed a new ophthalmic formulation of TGF-β1 assessing the ocular pharmacokinetic profile of TGF-β1 in the rabbit eye. Small unilamellar vesicles (SUV) loaded with TGF-β1 were complemented with Annexin V and Ca2+, and the vitreous bioavailability of TGF-β1 was assessed after topical ocular administration by a commercial ELISA kit. We detected high levels of TGF-β1 (Cmax 114.7 ± 12.40 pg/mL) in the vitreous after 60 min (Tmax) from the topical application of the liposomal suspension. Ocular tolerability was also assessed by a modified Draize’s test. The new formulation was well tolerated. In conclusion, we demonstrated that the novel formulation was able to deliver remarkable levels of TGF-β1 into the back of the eye after topical administration. Indeed, this TGF-β1 delivery system may be useful in clinical practice to manage ophthalmic conditions such as age-related macular degeneration, skipping invasive intraocular injections.

Cite

CITATION STYLE

APA

Platania, C. B. M., Fisichella, V., Fidilio, A., Geraci, F., Lazzara, F., Leggio, G. M., … Bucolo, C. (2017). Topical ocular delivery of TGF-β1 to the back of the eye: Implications in age-related neurodegenerative diseases. International Journal of Molecular Sciences, 18(10). https://doi.org/10.3390/ijms18102076

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free